Медикаментозная коррекция нарушений углеводного обмена: снижение риска сердечно-сосудистых осложнений
Медикаментозная коррекция нарушений углеводного обмена: снижение риска сердечно-сосудистых осложнений
Мычка В.Б., Чазова И.Е. Медикаментозная коррекция нарушений углеводного обмена: снижение риска сердечно-сосудистых осложнений. Consilium Medicum. 2008; 10 (11): 57–62.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Список литературы
1. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham Study. Circulation 1979; 59: 8–13.
2. Haffner S, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subject with type 2 diabetes and nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339: 229–34.
3. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346: 393–403.
4. Raskin P, Rendell M, Riddle MC et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24: 1226–32.
5. Barnett AH. Insulin-sensitizing agents – thiazolidinediones (glitazones). Curr Med Res Opin 2002; 18 (Suppl. 1): S31–9.
6. Everhart JE, Petitt DJ, Benneth PH et al. Duration of obesity increases the incidence of NIDDM. Diabetes 1992; 41: 235–40.
7. Dowse GK, Zimmet PZ, Gareebo H et al. Abdominal obesity and physical inactivity as risk factors for NIDDM and impaired glucose tolerance in Indian, Creole, and Chinese Mauritians. Diabetes Care 1991; 14: 271–82.
8. DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European Studies. Diabetologia. 1999; 42: 654–74.
9. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317: 703–13.
10. Chiasson J et al. The STOP-NIDDM trial. An international study on efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with IGT. Diabetes Care, 1998; 21: 1720–25.
11. И.Е.Чазова, В.Б.Мычка, Ю.Н.Беленков. Основные результаты программы АПРЕЛЬ. Системные гипертензии. 2005;7(2).
12. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317: 703–13.
2. Haffner S, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subject with type 2 diabetes and nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339: 229–34.
3. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346: 393–403.
4. Raskin P, Rendell M, Riddle MC et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24: 1226–32.
5. Barnett AH. Insulin-sensitizing agents – thiazolidinediones (glitazones). Curr Med Res Opin 2002; 18 (Suppl. 1): S31–9.
6. Everhart JE, Petitt DJ, Benneth PH et al. Duration of obesity increases the incidence of NIDDM. Diabetes 1992; 41: 235–40.
7. Dowse GK, Zimmet PZ, Gareebo H et al. Abdominal obesity and physical inactivity as risk factors for NIDDM and impaired glucose tolerance in Indian, Creole, and Chinese Mauritians. Diabetes Care 1991; 14: 271–82.
8. DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European Studies. Diabetologia. 1999; 42: 654–74.
9. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317: 703–13.
10. Chiasson J et al. The STOP-NIDDM trial. An international study on efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with IGT. Diabetes Care, 1998; 21: 1720–25.
11. И.Е.Чазова, В.Б.Мычка, Ю.Н.Беленков. Основные результаты программы АПРЕЛЬ. Системные гипертензии. 2005;7(2).
12. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317: 703–13.
Авторы
В.Б.Мычка, И.Е.Чазова
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.